Ticker Reports for March 10th
Is the Airline Stock Dip After the Iran Attacks Justified?
As the war in Iran appears likely to continue, it may be no surprise to investors that airline stocks have been among the first to feel a significant impact. These shares are closely tied to the cost of fuel, geopolitical stability, and consumer demand—all three of which are increasingly erratic as the war escalates and incorporates a broader geography. Both major carriers and even smaller domestic and regional names have seen their shares decline sharply: Delta Air Lines (NYSE: DAL) and American Airlines Group Inc. (NASDAQ: AAL) have dropped by about 22% and 27%, respectively, in the last month.
For investors, a price decline may present an opportunity to fortify a position in the airline industry. However, it will be crucial to consider whether the initial shock of the war—and the associated oil price worries—are sufficient to justify the selloff, despite a solid recent track record of domestic business. Relatedly, if a prolonged conflict might cause further declines, waiting to enter or build up a position in these stocks may be prudent instead.
Major Air Carriers Face Multiple Negative Drivers
Delta, American, and other major airlines have fared particularly badly since the start of the war due to the cumulative impact of multiple negative factors.
First, thousands of commercial flights to and from locations across the Middle East have been canceled—in these cases, airlines often face a range of operational and logistical costs while also dealing with lost revenue potential.
Second, and perhaps more importantly for business more broadly, is the increase in the cost of jet fuel. The Argus US Jet Fuel Index climbed to $3.88 on March 6 from $2.50 just a week before. While the crude oil market has faced significant volatility since the start of the conflict, the petroleum product space has been under even greater stress. Jet fuel prices and cracks—the latter referring to the differential between the price of crude oil and the price of the jet fuel derived from it—have soared.
Finally, consumer demand remains a somewhat more amorphous but still concerning factor. In its last earnings report, Delta was optimistic about demand even despite issues surrounding the government shutdown, thanks to loyalty and cargo growth, improvement in non-ticket revenue streams, and more.
Fellow Big Four member United Airlines (NASDAQ: UAL) was as well in its Q4 2025 report, citing its highest-ever seat completion factor and a 12% year-over-year (YOY) surge in premium revenue, for example.
As customers anticipate higher gasoline costs and increases in prices on a host of other products due to fluctuations in the oil market, investors may find it likely that leisure travel demand will sink while families divert cash to other necessary expenditures. The impact on the airline industry may not be felt immediately, but this could linger even after oil transport and inventories stabilize.
Can Regional Airlines Fare Any Better?
All of this is to say that even airline companies that are not particularly involved in operating in the Middle East region are likely to continue to be heavily impacted by the war. But what about those that operate domestically only, or those based in other countries?
Unfortunately, these companies have not fared much better, if at all, perhaps due to their dependence upon the price of fuel as well. One modest bright spot is shares of Air Canada (TSE: AC), which have only fallen by about 13% in the last month. However, this can hardly be considered a win for the industry.
Some Wall Street analysts have already begun to adjust their expectations accordingly—since the start of the month, for instance, Weiss has downgraded DAL shares to Hold from Buy and two other firms have lowered their price targets. Investors may choose to wait until prices have fallen further before entering a position.
It may also be valuable to watch for short interest trends as a way of gauging how the market believes share prices will behave going forward. Some companies, like American, were already facing increasing short interest prior to the start of the conflict, and this may be exacerbated.
Ultimately, depending upon how long the war continues and how it develops, the start of 2026 may feel eerily similar to the environment at the same time six years prior, as COVID-19 grounded the airline industry worldwide. To reach those levels, share prices would have to fall substantially farther than they already have. Bearish investors may wait to see how low airline stocks can fly.
The Missiles Are Flying. Is Your Retirement Protected?
The Missiles Are Flying. Is Your Retirement Protected?
Insiders Step in to Buy These 3 Tanking Stocks
Amid precipitous falls in their share prices, several key stocks are flashing bullish signals through a key indicator: insider buying. This includes a leading financial services company, a creative design disruptor, and a social media platform whose shares have soared by more than 300% in two years.
KKR Sees Big Insider Buying as Markets Rock Shares
KKR & Co. (NYSE: KKR) is the world’s fifth-largest alternative asset management company, controlling more than $700 billion in assets. However, the stock is down more than 35% from its all-time high, as artificial intelligence (AI) disruption fears rip through the market.
Specifically, investors worry that AI could hurt the businesses KKR invested in or loaned to, potentially significantly damaging their returns. This is particularly true of software investments, given the advent of “vibe-coding” and AI lab product releases.
Amid this, KKR insiders are aggressively buying the company’s stock. In 2026, insiders have purchased approximately $40 million worth of shares. Over the same period, MarketBeat has not tracked any insider selling.
This bullishness may come because KKR says its $740 billion in assets under management has only around 7% exposure to software. This is well below its industry, as well as equity and credit indexes, according to the company. Part of its underexposure here was due to the company’s cautiousness in 2021, when many in KKR’s industry overinvested in software businesses.
Still, there are other significant risks outside of software exposure, particularly the “Bermuda Triangle” private credit strategy used by firms like KKR that are worrisome.
FIG Insider Piles in After Fall from Grace
Next up is Figma (NYSE: FIG), a digital design company that has been challenging the dominance of Adobe (NASDAQ: ADBE).
The stock catapulted 250% on its first day of trading in mid-2025, but has since crashed. Overall, the stock has lost all of its first-day gains and more. It trades near $29 per share, solidly below its $33 IPO price. Notably, fears around AI software disruption have also hit Figma hard.
However, insider Reed Andrew Phillips is stepping in amid the carnage, purchasing over $36 million worth of Figma stock in February. Phillips bought these shares at an average price near $25, around 15% above the stock’s current level. Given the moderate move in Figma shares since then, these buys are likely still a bullish signal for investors.
On the other hand, it may concern investors that Figma’s insider selling in 2026 is near $50 million, exceeding Phillip's purchases. However, essentially all of these sales came under predetermined 10b5-1 plans or contained other mitigating circumstances. This limits the bearish signal that they provide, helping preserve the bullish sentiment surrounding Phillip’s purchases.
Still, as a recently public company, many insiders are looking to gain liquidity by selling their Figma shares, likely creating an overhang on the stock.
RDDT: Revenue, Margins, Buybacks, and Insider Buying Are Up
Discussion platform Reddit (NYSE: RDDT) has seen its share price go on an absolutely wild ride since going public in early 2024.
The stock shot up 48% in its first day of trading from its IPO price of $34. Shares reached as high as $270 in the second half of 2025. However, the stock has plummeted almost 50% from that level, now trading near $140. Still, shares remain up over 300% from their initial price.
AI disruption fears have likely also affected Reddit shares, with many of the stock’s biggest down days recently coinciding with significant drops in software names. Despite this, the company has generated rapid revenue growth of between 68% and 78% over the last three quarters on the back of its advertising revenue momentum. Reddit also posted its highest-ever adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) margin last quarter at 45%.
While the company indicated confidence going forward by announcing a new $1 billion buyback authorization, one insider is also providing a bullish signal.
In February, director Sarah Farrell purchased approximately $7.6 million worth of Reddit stock. Notably, Farrell bought these shares at an average price near $148, moderately above the stock’s current level. Reddit has also experienced significant insider selling in 2026. However, similar to Figma, essentially all of these came under 10b5-1 plans.
Evaluating Insider Activity Alongside Broader Fundamental Analysis
Overall, insider purchases at KKR, FIG, and RDDT are all positive signs for these stocks that have taken serious tumbles. However, investors should remember that insider purchases are just one important indicator to consider when evaluating individual stocks.
Elon Musk already made me a "wealthy man"
Elon Musk already made me a "wealthy man"
Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal
After falling 59% from its year-to-date (YTD) high, embattled healthcare stock Hims & Hers Health (NYSE: HIMS) is making headlines as shares are surging in the wake of an agreement with GLP-1 maker Novo Nordisk (NYSE: NVO)—the very company that filed a patent infringement lawsuit against Hims & Hers on Feb. 9.
After having to pull its compounded semaglutide modeled after Novo Nordisk’s weight loss drugs, Wegovy and Ozempic, Hims & Hers announced in a press release that the two firms have entered into a strategic partnership, making Novo Nordisk’s obesity drugs available through the telehealth platform.
Since the announcement, HIMS has gained nearly 46% along with analyst upgrades as Wall Street turns bullish on the direct-to-consumer prescription drug provider.
A Strategic Shift From Compounded GLP-1 to FDA-Approved Drugs
Amid surging demand and subsequent shortages for weight loss drugs, compounded GLP-1 alternatives emerged to fill the void. However, compounded GLP-1 drugs lack U.S. Food and Drug Administration (FDA) approval.
While they increased affordable access to substitutes for brand-name drugs like Ozempic and Wegovy, while offering similar ingredient profiles (e.g., semaglutide and tirzepatide, the latter of which is marketed as Mounjaro and Zepbound), the absence of FDA approval means that those alternative drugs lacked quality and efficacy reviews, thereby posing a risk of incorrect dosages, improper storage, and other safety issues.
According to Hims & Hers’s press release, as a part of the company’s shift away from compounded GLP-1 offerings, “existing patients will have the opportunity to transition to FDA-approved medicines.”
Specifically, “Hims & Hers has entered into an agreement with Novo Nordisk that will bring Ozempic (semaglutide) 0.5 mg, 1 mg, and 2 mg injections and Wegovy (semaglutide) pills and injections to the platform later this month, including 1.7 mg or 2.4 mg injections and 1.5 mg, 4 mg, 9 mg, and 25 mg tablets.”
Co-founder and CEO Andrew Dudum noted that the deal should result in “tremendous growth opportunities in the U.S. with the expanding assortment of branded GLP-1 medications.” Dudum added that the “collaboration reflects what’s possible globally when drugmakers, biotech companies, and diagnostic leaders partner with consumer platforms to support scaled distribution of their latest medical innovations.”
Shares of HIMS Are Still Struggling, But the Future Looks Promising
The recent news, as well as the sizable bump in the stock’s price, was warmly welcomed by shareholders who have dealt with Hims & Hers' volatility over the past year. Even in the wake of the Novo Nordisk-induced sell-off in February, analysts remained bullish on the stock, with some 12-month price targets implying as much as 150% potential upside.
Even with the March 9 surge, HIMS shares are still down nearly 33% over the last 12 months. But fundamentally, Hims & Hers looks well-positioned to sustain its run.
When the company reported full-year and Q4 2025 earnings on Feb. 23, it announced an earnings per share (EPS) beat and a revenue miss. EPS of 8 cents surpassed analyst expectations of 2 cents, while revenue of $617.82 million fell short of expectations of $619.48 million.
It was the company's first EPS beat since the first quarter of last year. But just as importantly, the financial metrics showed steady, sustainable revenue growth, with a three-year average of 64.60%. And while earnings contracted in 2025, that followed EPS growth of nearly 582% in 2024 and nearly 66% in 2023.
Hims & Hers Health’s earnings are expected to grow 79.31% next year, from 29 cents per share to 52 cents per share.
HIMS Receives Analyst Upgrades as Wall Street Turns Bullish on Telehealth
Following the announcement of the Novo Nordisk deal, Bank of America Securities upgraded HIMS stock to Neutral from Underperform and raised its price target to $23 from $12.50.
Notably, the firm’s previous price target excluded contributions from GLP-1 revenue, showing that the agreement with Novo Nordisk is being seen as an extremely bullish catalyst on Wall Street.
Overall, the stock receives a consensus Hold rating based on 17 analysts currently covering the stock. The average one-year price target implies more than 32% potential upside.
Current short interest of 43.24% of the shares outstanding should be monitored, but that figure—which equates to $1.32 billion worth of shares—is substantially lower than the $4.27 billion that were shorted last July. That downtrend has steadily continued, and it would not be surprising if institutional buyers once again outnumber sellers in the quarters ahead as the deal with Novo Nordisk will bolster Hims & Hers’ top-line growth.
Warning: You are not moving fast enough
Warning: You are not moving fast enough
MarketBeat Media, LLC dba TickerReport
345 N Reid Place, Suite 620, Sioux Falls, SD 57103.